arrow_back Back to App

Drug Importation: Lower Prices and Safer Access to Affordable Medicines.

This act aims to lower prescription drug prices in the U.S. by allowing safe importation from countries like Canada, the UK, the European Union, and Switzerland. This means citizens can buy medicines more affordably, either individually or through pharmacies and wholesalers, improving access and reducing financial burdens related to healthcare costs.
Key points
Legalizes the import of more affordable prescription drugs from selected countries, reducing healthcare costs for citizens.
Establishes oversight for foreign sellers and drug testing to ensure the safety of imported products.
Prohibits drug manufacturers from discriminating against foreign sellers who import drugs into the U.S., preventing artificial price increases.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_3162
Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]
Process start date: 2025-05-01
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable and Safe Prescription Drug Importation Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3162.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-05-01.

What are the main provisions?

Key points include:

  • Legalizes the import of more affordable prescription drugs from selected countries, reducing healthcare costs for citizens.
  • Establishes oversight for foreign sellers and drug testing to ensure the safety of imported products.
  • Prohibits drug manufacturers from discriminating against foreign sellers who import drugs into the U.S., preventing artificial price increases.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schakowsky, Janice D. [D-IL-9].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Economy